First IRB approval for APTN-101’s Ph 1 trial in GBM granted, enabling patient recruitment to begin January 25, 2026
Median OS Not Yet Reached and Lymphopenia Reversed in Recurrent GBM Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy January 25, 2026
Encouraging Clinical Results with In Situ Conversion Therapy NXL-004 for Malignant Glioma Reported December 22, 2025
Additional Positive LP-184 Ph 1a Results Reported Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients December 9, 2025
Preliminary Ph 2 Data for Silevertinib in 1L NSCLC and Plans for Ph 2 Trial of Silevertinib in GBM Announced December 9, 2025
Update from ongoing TEM-GBM study in newly diagnosed GBM patients with an unmethylated gene promoter announced December 2, 2025
FDA Grants Fast Track Designation to Zotiraciclib for Treatment of Recurrent High-Grade Glioma with IDH1/2 Mutations December 2, 2025
Ph 3 STELLAR clinical study results showing clinically meaningful benefits with eflornithine + lomustine in patients with grade 3 astrocytoma November 24, 2025
Following discussion with FDA, safusidenib vs vorasidenib trial in grade 2 IDH1-mutant glioma cancelled November 10, 2025
Positive Findings from Longer-Term Analysis of Ph 3 INDIGO Trial Showing Continued Durable Benefit of VORANIGO® (vorasidenib) Published in The Lancet Oncology November 10, 2025
Rare Pediatric Disease Designation from FDA for Iopofosine I 131 in R/R Pediatric High-Grade Glioma October 29, 2025
Type C meeting with FDA requested to discuss OS findings in 1L GBM patients treated with paxalisib and to discuss potential regulatory pathway per OCE’s Project FrontRunner initiative October 29, 2025
Positive Outcome From FORTE Basket Study of Plixorafenib Monotherapy in Recurrent or Progressive BRAF V600 Primary CNS Tumors Announced October 21, 2025
Cinetredekin besudotox Granted FDA Orphan Drug Designation by US FDA for Treatment of GBM October 16, 2025
ASTRO 2025: Final Results from Pivotal Ph 3 METIS Trial of TTFields Therapy for Brain Mets from NSCLC presented October 8, 2025
OmniaBio Inc. and BrainChild Bio Announce Collaboration to Accelerate CAR-T Cell therapy Development in Brain Cancer October 7, 2025
